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Transmissive spongiform encephalopathies (TSE) are neurodegenerative diseases character-
ized by depositions of abnormally folded prion protein (PrPTSE) in brain. PrPTSE is at present
the only speciﬁc biochemical marker of human and animal TSE. As deposits of PrPTSE remain
in the body for long periods, there is substantial chance of them being nonenzymatically mod-
iﬁed by glycation. The detection of glycated PrPTSE may have potential to serve as a diagnostic
marker. Monoclonal antibodies speciﬁc for carboxymethyl lysine/arginine-modiﬁed prion
protein were prepared. Recombinant human prion protein (rhPrP) was bacterially expressed
and puriﬁed by afﬁnity chromatography. rhPrP was modiﬁed by glyoxylic acid that introduces
carboxymethyl groups on lysine and arginine residues present within the molecule of the pro-
tein. Modiﬁed rhPrP (rhPrP-CML) was used for immunization of 6 mice, and 960 hybridoma
cells were prepared. Screening of cell supernatants resulted in the selection of four promising
clones. One of them (EM-31) strongly reacts with human and mouse recombinant PrP-CML,
and three other clones react also with CML in vitro modiﬁed human and mouse brain PrP.
Besides possible implication in TSE diagnostics, the antibodies may serve as tolls to advance
our knowledge regarding the role of glycation in the prion pathophysiology.
Transmissive spongiform encephalopathies
(TSE) are neurodegenerative diseases character-
ized by depositions of abnormally folded prion
protein (PrPTSE) in brain. The most frequent
human TSE is Creutzfeldt–Jakob disease (CJD),
and the diagnosis can only be deﬁnitively con-
ﬁrmed postmortem on brain tissues. Risk of
CJD transmission during neurosurgical interven-
tions and other invasive procedures constitutes
a serious problem. There have been reported
cases of CJD transmission due to transplanta-
tions of dura mater or cornea and due to use of
pituitary hormones or insufﬁcient sterilization
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of surgical tools (Brown et al. 2006; Armitage
et al. 2009). PrPTSE is at present the only speciﬁc
molecular marker of TSE. Detection of PrPTSE
usually depends on treatment of sample with
proteinase K or denaturing agents, which allows
distinguishing PrPTSE from normal cellular prion
protein (PrPC) (Grassi et al. 2008). These proce-
dures are time-consuming and difﬁcult to stan-
dardize. According to our hypothesis, glycated
prion protein may represent a new type of TSE
marker that could be visualized directly by a
speciﬁc monoclonal antibody without need for
proteinase K cleavage step.
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Glycation is a nonenzymatic binding of glu-
cose or other reducing sugars to free amino
groups of proteins. Initially created reversible
Schiff bases slowly form more stable and
covalently bound Amadori products that
remain in the organism for a long time with-
out being cleaved. Once formed, Amadori
products undergo further chemical rearrange-
ments and oxidations, which results in forma-
tion of advanced glycation end products (AGE)
(Monnier and Cerami 1981). Glycation occurs
mostly within side-chain amino groups of
lysines and arginines. One well-characterized
AGE product is N-(carboxymethyl)lysine (CML).
AGE play a key role in the pathogene-
sis of chronic diabetes mellitus complica-
tions (Brownlee et al. 1984) and glycated
hemoglobin HbA1c is the most important
diagnostic marker in diabetes compensation.
Glycation occurs in low amounts even in
healthy individuals on membrane proteins of
senescent erythrocytes (Ando et al. 1999), most
likely including also PrPC (Panigaj et al. 2011).
Erythrocytes live long (120 d), and due to
the lack of a protein synthesis they do not
replenish their proteins, leaving them suscep-
tible to glycation. Glycation was reported on
protein deposits in brains of patients with neu-
rodegenerative diseases such as Alzheimer and
Parkinson disease, systemic amyloidosis, and
prion diseases (Miranda and Outeiro 2009).
Protein deposits, remaining in the body for
a long time, are continuously exposed to
glucose and thus undergo glycation process.
Studies using pan-speciﬁc anti-AGE antibod-
ies have already demonstrated the presence of
glycation in prion brain deposits (Choi et al.
2004; Sasaki et al. 2002). The role of glycation
in prion pathogenesis is poorly understood.
Modiﬁcation of PrPC/PrPTSE with AGEs may
change their properties and affect their role in
the disease process. Availability of antibodies
speciﬁc for glycated prion protein, not reacting
with other glycated targets, is important step in
the effort directed on the elucidation of these
pending questions. This study was aimed on
development of monoclonal antibodies speciﬁc
for glycated human prion protein.
METHODS AND MATERIALS
Expression and Puriﬁcation of
Recombinant Prion Proteins
pRSET A plasmids with engineered throm-
bin cleavage site at the N-terminal histi-
dine tail and containing human sequences
for full-length prion protein 23–231 or prion
fragments 81–231, 90–231, and 121–231 were
kindly provided by Kurt Wüthrich (Zürich,
Switzerland). After transformation, Escherichia
coli BL21(DE3) (Stratagene) were cultivated
in Luria broth medium containing ampicilin
(100 µg/ml). Recombinant protein expres-
sion was induced by 1 mM isopropyl β-D-
galactopyranoside. Cells were harvested, resus-
pended in phosphate-buffered saline (PBS),
sonicated and inclusion bodies were isolated by
centrifugation as described previously (Pavlicek
et al. 2007). The recombinant prion proteins
(rhPrPs) were puriﬁed by afﬁnity chromatog-
raphy on Cu2+ resin (TALON, Clontech) in
denaturing conditions (8 M urea). The purity
of the proteins was analyzed by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and ultraviolet (UV) spectropho-
tometry. Full-length mouse recombinant prion
protein (rmPrP) was produced as described
previously (Pavlicek et al. 2007).
Glycation of Recombinant Prion Protein
In order to obtain carboxymethyl lysine-
modiﬁed rhPrP (rhPrP-CML) for immuniza-
tion, full-length rhPrP was incubated 16 h at
4◦Cw i t h4 5m M glyoxylic acid in 40 mM
phosphate buffer, pH 8, containing 1 mM
sodium cyanoborohydride (Ando et al. 1999).
Glycation of rmPrP was also performed by
its incubation with 1 M D-ribose (rmPrP-AGE)
under nitrogen (7 d, 37◦C).
Immunization of Mice
Six Prnp -/- (Zürich I) mice (EMMA,
Monterondo, Italy) were immunized sc on d
0, 14, and 28 with 30 µg rhPrP-CML in PBS
with Freund’s adjuvant. A ﬁnal booster of 5 µgANTIBODIES AGAINST GLYCATED PRION PROTEIN 1471
antigen in PBS was administered iv on d 64.
Mice were sacriﬁced on d 68 and splenic cells
from the 2 best responding mice were used for
fusion with myeloma cells. Nine hundred and
sixty hybridoma cells were prepared and used
for primary screening.
ELISA
For screening, rhPrP and rhPrP-CML were
diluted to 1 µg/ml in 50 mM sodium bicar-
bonate buffer, pH 9.6, and coated to NUNC
U96 MaxiSorp plates. For testing of speci-
ﬁcity of monoclonal antibodies (MAbs), rPrP ,
rPrP-CML, and bovine serum albumin (BSA)-
CML were diluted to 1 µg/ml and rmPrP-AGE
to 100 µg/ml. Wash steps were carried out
with 0.05% Tween 20 in PBS (PBS/T) and the
blocking step with 1% BSA in PBS/T. Mice
sera were diluted 1:5000 to 1:40,000 and
MAbs 1:500 to 1:128,000 in 0.1% BSA/PBS;
hybridoma supernatants were tested undi-
luted. The conjugate (Goat anti mouse IgG
[GAM] -horseradish peroxidase [HRP], Jackson
ImmunoResearch or Caltag) was diluted to
a ﬁnal concentration 0.125 µg/ml in PBS/T
and plates were developed with TMB sub-
strate (Amresco). Reaction was stopped with
1 M H2SO4 and absorbance was measured at
405 nm.
Western Blot (WB)
Human brain homogenate (hBh) was pre-
pared and the Western blot (WB) was car-
ried out as described previously (Panigaj
et al. 2011). Eventually, proteins were glycated
directly on the nitrocellulose membrane (16 h
at 4◦C) by 50 mM glyoxylic acid and 50 mM
sodium cyanoborohydride. Membrane was
blocked and incubated for 1 h at room tem-
perature with clone supernatants diluted 1:10.
Monoclonal antibodies (MAbs) 3F4 (Chemicon,
Inc., Temecula, CA) and AG4 (TSE Resource
Center, Compton, UK) were used as positive
controls.
Screening Procedure
Fifty-three clones selected in primary
screening by enzyme-linked immunosorbent
assay (ELISA) were tested in secondary screen-
ing by WB on rhPrP and rhPrP-CML. Tertiary
screening was conducted by WB and dot-blot
on biological material, such as 1% normal hBh,
1% mouse brain homogenates (mBh, WT, and
Prnp -/-), human platelets (109/ml), red blood
cell ghosts (1010/ml), and BSA (0.5 mg/ml).
Selected samples were glycated directly on the
membrane as described earlier.
RESULTS AND DISCUSSION
Development of antibodies against prion
protein was often hampered by its poor
immunogenicity due to the highly conserved
primary structure of the protein among differ-
ent mammal species. To overcome this poten-
tial problem, Prnp -/- mice were used and
immunized with rhPrP-CML. CML represents
the end-stage product of protein glycation and
is the most abundant AGE antigen in vivo
(Reddy et al. 1995). Out of six immunized
mice, two had high, three medium, and one
low titer antibody response to the immuniza-
tion. The reactivity of antibodies to hrPrP-
CML in sera of both high-responding mice
was numerically higher than the reactivity to
unmodiﬁed hrPrP (e.g., A405 = 1.5 versus
A405 = 1.1 at 5 × 10−5 dilution), suggest-
ing the presence of antibodies directed against
CML (data not shown). Primary ELISA screen-
ing of 960 hybridomas resulted in the selec-
tion of 53 clones demonstrating production
of MAbs with different afﬁnities to unmodi-
ﬁed and CML modiﬁed rhPrP . Secondary WB
screening selected 12 clones, and among them
4 clones (7A8, 1C3, 1C12, and 1F3) displayed
high speciﬁcity to rhPrP-CML. Experiments ini-
tially concentrated on characterization of MAb
EM-31 produced by clone 7A8, which demon-
strated the highest reactivity to rhPrP-CML.
MAb EM-31 displayed strong binding to hrPrP-
CML on WB, while its binding to unmodiﬁed
hrPrP was negligible (Figure 1a). EM-31 did not
bind to BSA-CML, either on WB (Figure 1a) or
ELISA (Figure 1f), suggesting that the binding
is speciﬁc for PrP-CML. The antibody cross-
reacted with mrPrP-CML(Figure 1a) and also1472 E. DVORAKOVA ET AL.
FIGURE 1. Characterization of MAb EM-31 binding to glycated prion proteins by Western blot and ELISA. (a) Three identical blots
developed with EM-31, control prion antibody 6H4, or stained for proteins with colloidal silver (Ag). Lines: 1, normal mouse brain
homogenate (mBh); 2, normal human brain homogenate (hBh); 3, recombinant mouse PrP (rmPrP); 4, glycated rmPrP (rmPrP-CML);
5, recombinant human PrP (rhPrP); 6, glycated rhPrP (rhPrP-CML); 7, glycated BSA (BSA-CML). EM-31 reacts only with glycated rPrPs.
(b) Two identical blots developed with MAb EM-31 and control prion MAb AG4. Lines: 8, reduced rmPrP-CML; 9, reduced rmPrP-AGE
(glycated by incubation with ribose); 10, nonreduced rmPrP after incubation with ribose in Tris buffer (glycation inhibited); 11, glycated
nonreduced rmPrP after incubation with ribose in phosphate buffer. Reactivity of EM-31 with rmPrP-CML and rmPrP-AGE is lost after
reduction of samples with dithiothreitol. (c) EM-31 reacts with C-terminal fragments of rhPrP-CML molecule: 23–231 (lane 12), 81–231
(lane 13), 90–231 (lane 14), and 121–231 (lane 15). (d) Time course of rmPrP modiﬁcation by incubation with 1 M D-ribose detected
by EM-31. (e) EM-31 has only a weak afﬁnity to PrP in glycated human brain homogenate (hBh-CML) (lane 16). MAb 3F4 is used as a
control of glycation. It binds to PrP in nonglycated hBh (lane 17), but not in hBh-CML (lane 18). MAb AG4 is a glycation insensitive control
detecting PrP in hBh-CML (lane 19). (f) Demonstration of the speciﬁcity of EM-31 for glycated prion protein by ELISA. Wells of the plate
were coated by rhPrP , rmPrP , rhPrP-CML, rmPrP-CML, rmPrP-AGE, or BSA-CML and developed with increasing concentrations of MAbs:
EM-31 (rectangles, dotted line), glycation-sensitive 3F4 (triangles, dashed line), and glycation-insensitive AG4 (circles, full line). Labeling
in rmPrP-AGE ﬁgure is AG4 (circles, full line), 3F4 (inverted triangles, dashed line), and two batches of EM-31 (rectangles, dashed and
dotted line, and triangles, dashed and double dotted line). EM-31 does not bind to unmodiﬁed proteins and the reactivity of 3F4 to rhPrP
is lost after its modiﬁcation. Neither MAb binds to glycated BSA.
with mrPrP-AGE prepared by glycation of the
protein with D-ribose (Figures 1b and 1d). This
conﬁrmed that the antibody recognizes also
rPrP glycated by milder, more natural proce-
dure. EM-31 does not bind to reduced rhPrP-
CML nor to reduced rmPrP-CML or rmPrP-AGE
(Figure 1b), which implicates that the epitope
of EM-31 is not linear and may include the
disulﬁde bond between Cys179 and Cys214.
EM-31 reacted with all rhPrP-CML fragments
tested, including rhPrP121–231-CML, conﬁrm-
ing the location of its epitope on C-terminal
part of PrP molecule (Figure 1c). Importantly,
EM-31 did not cross-react with any protein
on blots of normal hBh or mBh (Figure 1a).
Recently, Panigaj et al. (2011) obtained evi-
dence that the epitope of MAb 3F4 (PrP106–112)
on PrPC on the membrane of human redANTIBODIES AGAINST GLYCATED PRION PROTEIN 1473
blood cells is covalently modiﬁed, likely by
glycation. However, EM-31 did not bind to
human red blood cell or platelet PrPC on
WB (data not shown). This raises a ques-
tion regarding the location of glycation sites
in the PrP molecule. Human mature PrP con-
tains 10 lysine and 10 arginine residues, which
are fairly scattered along its sequence and
can in theory be glycated. Previous study by
Choi et al. (2004) demonstrated the presence
of glycation in one or more lysine residues
of the PrPTSE N-terminus. Whether also other
putative glycation sites are modiﬁed during
the disease process remains to be elucidated.
Interestingly, EM-31 bound poorly to in vitro
glycated PrPC in hBh (Figure 1a). This was
not produced by improper modiﬁcation of PrP ,
as MAb 3F4 lost its reactivity (Panigaj et al.
2011), while the protein was still recognized
by glycation-insensitive MAb 6H4 (Figure 1a).
A plausible explanation of this phenomenon
may lie in the shielding effect of glycosylation
of asparagines N181 and N197 in PrPC, which
is not present in recombinant protein. While
this ﬁnding may limit the usefulness of EM-
31 for the detection of in vivo glycated glyco-
sylated isoforms of PrPC/PrPTSE, it also suggests
that EM-31 may represent a useful tool for
studies of glycation of unglycosylated isoform
of the protein. Recently, properties of MAbs
produced by the other selected hybridoma
clones 1C3, 1C12, and 1F3 were analyzed.
Generally, MAbs exhibited properties similar
to those of EM-31 with two important dis-
tinctions. MAbs were able to recognize not
only hrPrP-CML (Figure 2a), but also glycosy-
lated PrPC-CML on blots of in vitro modiﬁed
hBh (Figure 2b) or mBh (not shown). In addi-
tion, their binding was not sensitive to pro-
tein reduction by dithiothreitol (not shown).
The speciﬁcity of their binding to glycated
rhPrP was conﬁrmed by ELISA (Figure 2d). All
clones reacted more strongly with rhPrP-CML
than with rhPrP90–231-CML or rhPrP81–231-CML
FIGURE 2. Three hybridoma supernatants demonstrate afﬁnity to PrP in the in vitro glycated human brain homogenate. (a) Western blot
of rhPrP was cut in strips and strips 1–3 were glycated by incubation with glyoxylic acid while strips 4–9 were left untreated. Supernatants
1C3, 1C12, and 1F3 demonstrate strong reactivity with the PrP on treated strips (1–3), but only faint reactivity with untreated rhPrP (7–9).
The presence of the rhPrP is conﬁrmed by MAbs 6H4, 3F4, and AG4 (4–6). (b) Clones 1C3, 1C12, and 1F3 recognize PrP in the in
vitro glycated human brain homogenate (hBh-CML, lanes 11, 13, 15), but not in untreated hBh (lanes 10, 12, 14). MAb 3F4 is used as a
control for glycation. It binds to PrP in nonglycated hBh (lane 16), but not in hBh-CML (lane 17). MAb AG4 is a positive control for PrP
in hBh-CML (lane 18). (c) The reactivity of all three clones with glycated C-terminal fragments rhPrP81–231 and rhPrP90–231 on dot-blots
is weaker than with rhPrP23–231-CML. (d) Demonstration of 1C3, 1C12, and 1F3 reactivity with rhPrP-CML by ELISA. Wells of the plate
were coated with rhPrP or rhPrP-CML and developed with increasing dilutions of MAb: 6H4, glycation insensitive (circle, full line); 3F4,
glycation sensitive (diamond, dashed line); 1C3 (inverted triangle, dashed and double dotted line); 1C12 (triangle, dashed and dotted
line); and 1F3 (rectangle, dotted line). Reactivity of 3F4 after glycation is lost, while the reactivity of the MAbs produced by the tested
clones increases.1474 E. DVORAKOVA ET AL.
(Figure 2c), suggesting that their epitopes could
be located on N-terminal half of the PrP
molecule; however, this point must be inde-
pendently veriﬁed.
In conclusion, it was shown that the devel-
opment of monoclonal antibodies speciﬁc for
glycated prion protein is feasible. At the present
time, studies are continuing in the basic char-
acterization of MAbs produced by clones 1C3,
1C12, and 1F3, while the MAb EM-31 was
puriﬁed and made commercially available
(EXBIO Praha a.s., Vestec, Czech Republic).
Our project is primarily aimed at the devel-
opment of antibodies useful for detection of
in vivo glycated PrPTSE, so an important next
step will be to test our MAbs on samples of
CJD patients and TSE-infected laboratory ani-
mals. Eventual success of these studies may lead
to the development of a new diagnostic test
for prion diseases. Beside this, our antibodies
may serve as basic tools in elucidation of the
role of glycation of prion protein in the TSE
pathogenesis.
Glycation is thought to stabilize protein
deposits in different neurodegenerative dis-
orders including TSE (Miranda and Outeiro
2009). On the other hand, glycation of PrPC
is likely ongoing in red blood cells (Ando
et al. 1999; Panigaj et al. 2011) and may
modify its properties, e.g., afﬁnity for PrPTSE.
As red blood cells possess the majority of cell-
associated PrPC in blood, not only in humans
(Panigaj et al. 2011) but also in laboratory
mice and nonhuman primates (Holada et al.
2007), such a change in its properties could
play an important role in the transmission
of TSE by blood transfusion. Detailed stud-
ies of the effect of glycation on the structure
and stability of recombinant PrP should pro-
vide useful starting data, which will further our
understanding of this interesting area of prion
pathophysiology.
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